Canopy Growth Corp (NYSE:CGC) gets downgraded to Neutral by Bryan, Garnier & Co

Analyst Ratings For Canopy Growth Corp (NYSE:CGC)

Story continues below

Today, Canopy Growth Corp (NYSE:CGC) stock was downgraded by Bryan, Garnier & Co from Buy to Neutral.

There are 9 Buy Ratings, 7 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Canopy Growth Corp (NYSE:CGC) is Buy with a consensus target price of $63.3038 per share, a potential 54.17% upside.

Some recent analyst ratings include

  • 7/5/2019-Canopy Growth Corp (NYSE:CGC) gets downgraded to Neutral by Bryan, Garnier & Co
  • 6/28/2019-Canopy Growth Corp (NYSE:CGC) has coverage initiated with a Equal Weight ➝ Equal Weight rating
  • 6/24/2019-Canopy Growth Corp (NYSE:CGC) had its Hold rating reiterated by Desjardins
  • 6/12/2019-Canopy Growth Corp (NYSE:CGC) has coverage initiated with a Outperform rating and $107.57 price target
  • 6/10/2019-Canopy Growth Corp (NYSE:CGC) has coverage initiated with a Neutral rating and $43.76 price target

    About Canopy Growth Corp (NYSE:CGC)
    Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. Read More…

    Recent Trading Activity for Canopy Growth Corp (NYSE:CGC)
    Shares of Canopy Growth Corp closed the previous trading session at 41.06 up +0.98 2.45% with 38.08 shares trading hands.

    An ad to help with our costs